{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:57:08Z","timestamp":1789192628683,"version":"build-2803163510"},"posted":{"date-parts":[[2020,9,16]]},"group-title":"Biochemistry","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  There is an urgent need for vaccines and antiviral drugs to combat the COVID-19 pandemic. Encouraging progress has been made in developing antivirals targeting SARS-CoV-2, the etiological agent of COVID-19. Among the drug targets being investigated, the viral main protease (M\n                  <jats:sup>pro<\/jats:sup>\n                  ) is one of the most extensively studied drug targets. M\n                  <jats:sup>pro<\/jats:sup>\n                  is a cysteine protease that hydrolyzes the viral polyprotein at more than 11 sites and it is highly conserved among coronaviruses. In addition, M\n                  <jats:sup>pro<\/jats:sup>\n                  has a unique substrate preference for glutamine in the P1 position. Taken together, it appears that M\n                  <jats:sup>pro<\/jats:sup>\n                  inhibitors can achieve both broad-spectrum antiviral activity and a high selectivity index. Structurally diverse compounds have been reported as M\n                  <jats:sup>pro<\/jats:sup>\n                  inhibitors, with several of which also showed antiviral activity in cell culture. In this study, we investigated the mechanism of action of six previously reported M\n                  <jats:sup>pro<\/jats:sup>\n                  inhibitors, ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12 using a consortium of techniques including FRET-based enzymatic assay, thermal shift assay, native mass spectrometry, cellular antiviral assays, and molecular dynamics simulations. Collectively, the results showed that the inhibition of M\n                  <jats:sup>pro<\/jats:sup>\n                  by these six compounds is non-specific and the inhibition is abolished or greatly reduced with the addition of reducing reagent DTT. In the absence of DTT, these six compounds not only inhibit M\n                  <jats:sup>pro<\/jats:sup>\n                  , but also a panel of viral cysteine proteases including SARS-CoV-2 papain-like protease, the 2A\n                  <jats:sup>pro<\/jats:sup>\n                  and 3C\n                  <jats:sup>pro<\/jats:sup>\n                  from enterovirus A71 (EV-A71) and EV-D68. However, none of the compounds inhibits the viral replication of EV-A71 or EV-D68, suggesting that the enzymatic inhibition potency IC\n                  <jats:sub>50<\/jats:sub>\n                  values obtained in the absence of DTT cannot be used to faithfully predict their cellular antiviral activity. Overall, we provide compelling evidence suggesting that ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12 are non-specific SARS-CoV-2 M\n                  <jats:sup>pro<\/jats:sup>\n                  inhibitors, and urge the scientific community to be stringent with hit validation.\n                  <jats:fig id=\"ufig1\" position=\"float\" fig-type=\"figure\" orientation=\"portrait\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"299164v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:p>","DOI":"10.1101\/2020.09.15.299164","type":"posted-content","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T04:20:30Z","timestamp":1600316430000},"source":"Crossref","is-referenced-by-count":10,"title":["Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors"],"prefix":"10.64898","author":[{"given":"Chunlong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Alma","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis I.","family":"Lagarias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Thomas","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Kolocouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4621","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024080416155447000_2020.09.15.299164v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"2024080416155447000_2020.09.15.299164v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0820-9"},{"key":"2024080416155447000_2020.09.15.299164v1.3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3389\/fphar.2020.00937","article-title":"A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic","volume":"11","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"2024080416155447000_2020.09.15.299164v1.4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases","volume":"6","year":"2020","journal-title":"ACS Cent Sci"},{"key":"2024080416155447000_2020.09.15.299164v1.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003138117"},{"key":"2024080416155447000_2020.09.15.299164v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"2024080416155447000_2020.09.15.299164v1.7","doi-asserted-by":"crossref","unstructured":"Liu, T. ; Luo, S. ; Libby, P. ; Shi, G. P. , Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacol Ther 2020, 107587.","DOI":"10.1016\/j.pharmthera.2020.107587"},{"key":"2024080416155447000_2020.09.15.299164v1.8","doi-asserted-by":"crossref","unstructured":"Sheahan, T. P. ; Sims, A. C. ; Graham, R. L. ; Menachery, V. D. ; Gralinski, L. E. ; Case, J. B. ; Leist, S. R. ; Pyrc, K. ; Feng, J. Y. ; Trantcheva, I. ; Bannister, R. ; Park, Y. ; Babusis, D. ; Clarke, M. O. ; Mackman, R. L. ; Spahn, J. E. ; Palmiotti, C. A. ; Siegel, D. ; Ray, A. S. ; Cihlar, T. ; Jordan, R. ; Denison, M. R. ; Baric, R. S. , Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017, 9 (396).","DOI":"10.1126\/scitranslmed.aal3653"},{"key":"2024080416155447000_2020.09.15.299164v1.9","doi-asserted-by":"crossref","unstructured":"Sheahan, T. P. ; Sims, A. C. ; Zhou, S. ; Graham, R. L. ; Pruijssers, A. J. ; Agostini, M. L. ; Leist, S. R. ; Schafer, A. ; Dinnon, K. H. , 3rd; Stevens, L. J. ; Chappell, J. D. ; Lu, X. ; Hughes, T. M. ; George, A. S. ; Hill, C. S. ; Montgomery, S. A. ; Brown, A. J. ; Bluemling, G. R. ; Natchus, M. G. ; Saindane, M. ; Kolykhalov, A. A. ; Painter, G. ; Harcourt, J. ; Tamin, A. ; Thornburg, N. J. ; Swanstrom, R. ; Denison, M. R. ; Baric, R. S. , An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020, 12 (541).","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"2024080416155447000_2020.09.15.299164v1.10","unstructured":"Rut, W. ; Groborz, K. ; Zhang, L. ; Sun, X. ; Zmudzinski, M. ; Hilgenfeld, R. ; Drag, M. , Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design. bioRxiv 2020, 2020.03.07.981928."},{"issue":"8","key":"2024080416155447000_2020.09.15.299164v1.11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","year":"2020","journal-title":"Cell Res"},{"key":"2024080416155447000_2020.09.15.299164v1.12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors","volume":"582","year":"2020","journal-title":"Nature"},{"issue":"6497","key":"2024080416155447000_2020.09.15.299164v1.13","first-page":"1331","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"369","year":"2020","journal-title":"Science"},{"key":"2024080416155447000_2020.09.15.299164v1.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3405"},{"key":"2024080416155447000_2020.09.15.299164v1.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02574-15"},{"issue":"69","key":"2024080416155447000_2020.09.15.299164v1.16","doi-asserted-by":"crossref","first-page":"10214","DOI":"10.1039\/C9CC04145A","article-title":"Targeting the Mycobacterium tuberculosis transpeptidase LdtMt2 with cysteine-reactive inhibitors including ebselen","volume":"55","year":"2019","journal-title":"Chem Commun"},{"key":"2024080416155447000_2020.09.15.299164v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.fob.2014.01.002"},{"key":"2024080416155447000_2020.09.15.299164v1.18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9103"},{"issue":"5","key":"2024080416155447000_2020.09.15.299164v1.19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/acsinfecdis.7b00003","article-title":"Exploring Covalent Allosteric Inhibition of Antigen 85C from Mycobacterium tuberculosis by Ebselen Derivatives","volume":"3","year":"2017","journal-title":"ACS Infect Dis"},{"key":"2024080416155447000_2020.09.15.299164v1.20","doi-asserted-by":"publisher","DOI":"10.1021\/cb500512z"},{"key":"2024080416155447000_2020.09.15.299164v1.21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejmech.2019.06.057","article-title":"Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening","volume":"179","year":"2019","journal-title":"Eur J Med Chem"},{"key":"2024080416155447000_2020.09.15.299164v1.22","doi-asserted-by":"crossref","unstructured":"Zmudzinski, M. ; Rut, W. ; Olech, K. ; Granda, J. ; Giurg, M. ; Burda-Grabowska, M. ; Zhang, L. ; Sun, X. ; Lv, Z. ; Nayak, D. ; Kesik-Brodacka, M. ; Olsen, S. ; Hilgenfeld, R. ; Drag, M. , Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies. bioRxiv 2020, 2020.08.30.273979.","DOI":"10.1101\/2020.08.30.273979"},{"issue":"3","key":"2024080416155447000_2020.09.15.299164v1.23","first-page":"692","article-title":"Disulfiram is a direct and potent inhibitor of human O 6 -methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage","volume":"35","year":"2013","journal-title":"Carcinogenesis"},{"key":"2024080416155447000_2020.09.15.299164v1.24","doi-asserted-by":"crossref","unstructured":"Diaz-Sanchez, A. G. ; Alvarez-Parrilla, E. ; Martinez-Martinez, A. ; Aguirre-Reyes, L. ; Orozpe-Olvera, J. A. ; Ramos-Soto, M. A. ; Nunez-Gastelum, J. A. ; Alvarado-Tenorio, B. ; de la Rosa, L. A. , Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans. Molecules 2016, 21 (12).","DOI":"10.3390\/molecules21121628"},{"key":"2024080416155447000_2020.09.15.299164v1.25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.553123"},{"key":"2024080416155447000_2020.09.15.299164v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.12.015"},{"issue":"2","key":"2024080416155447000_2020.09.15.299164v1.27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acs.jmedchem.8b01723","article-title":"Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur","volume":"62","year":"2019","journal-title":"J Med Chem"},{"key":"2024080416155447000_2020.09.15.299164v1.28","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0486"},{"key":"2024080416155447000_2020.09.15.299164v1.29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.306472"},{"issue":"6","key":"2024080416155447000_2020.09.15.299164v1.30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"2024080416155447000_2020.09.15.299164v1.31","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease","volume":"6","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"11","key":"2024080416155447000_2020.09.15.299164v1.32","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1021\/acsinfecdis.9b00284","article-title":"A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68","volume":"5","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"7","key":"2024080416155447000_2020.09.15.299164v1.33","first-page":"e02221","article-title":"Validating Enterovirus D68-2A(pro) as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2A(pro) Inhibitor","volume":"93","year":"2019","journal-title":"J Virol"},{"issue":"8","key":"2024080416155447000_2020.09.15.299164v1.34","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1021\/acsinfecdis.0c00383","article-title":"Pharmacological Characterization of the Mechanism of Action of R523062, a Promising Antiviral for Enterovirus D68","volume":"6","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2024080416155447000_2020.09.15.299164v1.35","doi-asserted-by":"crossref","unstructured":"Zhou, Q. A. ; Kato-Weinstein, J. ; Li, Y. ; Deng, Y. ; Granet, R. ; Garner, L. ; Liu, C. ; Polshakov, D. ; Gessner, C. ; Watkins, S. , Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. ACS Pharmacol Transl Sci 2020, asap.","DOI":"10.1021\/acsptsci.0c00074"},{"key":"2024080416155447000_2020.09.15.299164v1.36","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X17729626"},{"key":"2024080416155447000_2020.09.15.299164v1.37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005531"},{"issue":"9","key":"2024080416155447000_2020.09.15.299164v1.38","doi-asserted-by":"crossref","first-page":"e0162771","DOI":"10.1371\/journal.pone.0162771","article-title":"Enterovirus A71 DNA-Launched Infectious Clone as a Robust Reverse Genetic Tool","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"2024080416155447000_2020.09.15.299164v1.39","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5b00140"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.09.15.299164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:50:50Z","timestamp":1768438250000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2020.09.15.299164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1101\/2020.09.15.299164","relation":{},"subject":[],"published":{"date-parts":[[2020,9,16]]},"subtype":"preprint"}}